Zealand Pharma A/S

OTCPK:ZLDP.F Stock Report

Market Cap: US$6.7b

Zealand Pharma Valuation

Is ZLDP.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZLDP.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ZLDP.F ($95.38) is trading above our estimate of fair value ($23.09)

Significantly Below Fair Value: ZLDP.F is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZLDP.F?

Key metric: As ZLDP.F barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ZLDP.F. This is calculated by dividing ZLDP.F's market cap by their current book value.
What is ZLDP.F's PB Ratio?
PB Ratio5.4x
BookDKK 8.88b
Market CapDKK 47.79b

Price to Book Ratio vs Peers

How does ZLDP.F's PB Ratio compare to its peers?

The above table shows the PB ratio for ZLDP.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average11.7x
ROIV Roivant Sciences
1.6x-40.6%US$8.2b
HALO Halozyme Therapeutics
12x21.1%US$5.8b
BPMC Blueprint Medicines
18.3x68.6%US$5.6b
IMGN ImmunoGen
14.9x45.8%US$8.4b
ZLDP.F Zealand Pharma
5.4x65.8%US$47.8b

Price-To-Book vs Peers: ZLDP.F is good value based on its Price-To-Book Ratio (5.4x) compared to the peer average (11.7x).

Price to Book Ratio vs Industry

How does ZLDP.F's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$497.29m
AMRN Amarin
0.4x-7.7%US$205.67m
IMAB I-Mab
0.4x1.8%US$84.69m
ACET Adicet Bio
0.4x6.7%US$78.03m
ZLDP.F 5.4xIndustry Avg. 1.8xNo. of Companies81PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ZLDP.F is expensive based on its Price-To-Book Ratio (5.4x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is ZLDP.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZLDP.F PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ZLDP.F's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ZLDP.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$95.38
US$143.74
+50.7%
10.8%US$155.24US$115.02n/a10
Nov ’25US$119.76
US$147.06
+22.8%
11.7%US$161.38US$116.73n/a9
Oct ’25US$123.00
US$151.22
+22.9%
10.3%US$163.61US$118.34n/a7
Sep ’25US$126.00
US$150.00
+19.0%
10.0%US$163.42US$118.21n/a7
Aug ’25US$131.39
US$143.14
+8.9%
9.6%US$159.06US$115.68n/a7
Jul ’25US$133.00
US$131.72
-1.0%
12.2%US$157.84US$114.79n/a6
Jun ’25US$92.98
US$114.48
+23.1%
8.9%US$122.41US$91.08n/a7
May ’25US$87.66
US$112.20
+28.0%
10.0%US$120.53US$86.09n/a7
Apr ’25US$98.86
US$109.28
+10.5%
14.4%US$121.70US$82.58n/a7
Mar ’25US$95.90
US$86.81
-9.5%
26.1%US$116.01US$55.39n/a6
Feb ’25US$69.00
US$61.71
-10.6%
11.2%US$70.69US$51.75n/a6
Jan ’25US$55.65
US$54.70
-1.7%
11.7%US$62.07US$42.58n/a6
Dec ’24US$47.92
US$53.31
+11.3%
9.3%US$58.37US$43.05n/a6
Nov ’24US$42.84
US$48.71
+13.7%
9.3%US$53.83US$41.79US$119.766
Oct ’24US$43.46
US$48.71
+12.1%
9.3%US$53.83US$41.79US$123.006
Sep ’24US$37.30
US$45.89
+23.0%
12.5%US$55.44US$39.39US$126.006
Aug ’24US$33.42
US$43.27
+29.5%
11.4%US$49.84US$34.45US$131.396
Jul ’24US$34.55
US$43.27
+25.2%
11.4%US$49.84US$34.45US$133.006
Jun ’24US$38.25
US$43.27
+13.1%
11.4%US$49.84US$34.45US$92.986
May ’24US$33.40
US$42.93
+28.5%
11.3%US$50.02US$34.57US$87.666
Apr ’24US$34.88
US$42.83
+22.8%
11.3%US$48.48US$34.21US$98.865
Mar ’24US$32.00
US$36.65
+14.5%
5.3%US$39.17US$33.47US$95.906
Feb ’24US$30.57
US$36.77
+20.3%
5.9%US$40.18US$34.19US$69.006
Jan ’24US$28.18
US$34.40
+22.1%
8.9%US$39.17US$29.20US$55.656
Dec ’23US$28.50
US$31.30
+9.8%
11.2%US$36.50US$26.55US$47.926
Nov ’23US$27.00
US$31.30
+15.9%
11.2%US$36.50US$26.55US$42.846

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Collegium Pharmaceutical

US$954.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.22

7D

-9.2%

1Y

14.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.25

7D

-10.5%

1Y

7.7%

Teva Pharmaceutical Industries

US$18.6b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.49

7D

-5.1%

1Y

74.5%